Zealand initiates new study with SBS drug
Danish biotech Zealand Pharma has initiated a new clinical trial with a long-acting version of its GLP-2 analogue glepaglutide against short bowel syndrome. The company expects to take the candidate to phase III in 2018.
BY LONNI PARK LYNGE
Zealand Pharma has dosed the first 30 participants in a new clinical trial with the GLP-2 analogue glepaglutide against short bowel syndrome. This is according to a press release from the company.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Zealand Pharma planned for success
For abonnenter
Zealand carries out USD 89m IPO in the US
For abonnenter
Zealand sees big potential for SBS drug
For abonnenter
